8-K: TScan Therapeutics Announces Positive Phase 1 Trial Results and Outlines Pivotal Study Design for TCR-T Therapies

TScan Therapeutics reported promising updated data from its ALLOHA Phase 1 trial, showing a significant reduction in relapse rates for patients receiving their TCR-T therapies, and announced plans for a pivotal trial in the second half of 2025.

Summary

• TScan Therapeutics presented updated results from its ongoing ALLOHA Phase 1 trial for TSC-100 and TSC-101, which are designed to treat residual disease and prevent relapse in patients with certain blood cancers after hematopoietic cell transplantation (HCT).
• The trial enrolled 38 patients, with 26 in the treatment arm receiving either TSC-100 or TSC-101 and 12 in the control arm receiving HCT alone.
• Event-free survival strongly favored the treatment arm with a hazard ratio of 0.30 and a p-value of 0.04, indicating a significant reduction in events such as relapse or death.
• Early trends suggest a lower probability of relapse in the treatment arm with a hazard ratio of 0.28 and a p-value of 0.14.
• Only 8% of patients in the treatment arm relapsed compared to 33% in the control arm.
• The median time to relapse was not reached in the treatment arm, while it was 160 days in the control arm.
• The company has received feedback from the FDA regarding a potential registrational pathway, and plans to launch a pivotal trial in the second half of 2025.
• The pivotal trial will focus on TSC-101, which covers a large portion of the patient population, and will use relapse-free survival as the primary endpoint.
• The company also provided an update on its solid tumor program, highlighting early signs of anti-tumor activity and plans to investigate multiplexed therapy in 2025.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results and a clear path forward for the company's lead program. The planned pivotal trial and expansion of the ImmunoBank are also encouraging. However, there are some risks and uncertainties associated with the development of novel therapies, which temper the overall sentiment.

Positives

• The ALLOHA Phase 1 trial showed strong efficacy signals with a significant reduction in relapse rates and improved event-free survival.
• The treatment was well-tolerated with no dose-limiting toxicities.
• The company has a clear path to a registrational trial based on FDA feedback.
• The company is expanding its ImmunoBank of TCRs to enable multiplex TCR-T therapy for solid tumors.
• The company has successfully manufactured its first T-Plex product.

Negatives

• One treatment-arm relapse resulted in mortality in a high-risk patient who was taken to transplant without achieving complete remission.
• Another treatment-arm relapse was an extramedullary relapse in the central nervous system with no evidence of systemic relapse.
• The solid tumor program is still in early stages with limited data.

Risks

• The pivotal trial design is subject to further feedback from regulatory authorities.
• The company's ability to successfully manufacture and scale up production of its TCR-T therapies is critical.
• The company faces competition in the development of TCR-T therapies.
• The company's financial performance and ability to fund its operations are subject to risks and uncertainties.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company plans to launch a pivotal trial for TSC-101 in the second half of 2025 and continue to expand its ImmunoBank for solid tumor therapies, with the goal of achieving clearly interpretable data in defined areas by the end of 2025.

Management Comments

• Chrystal U. Louis, M.D., Chief Medical Officer, stated that disease relapse is the leading cause of death in patients undergoing transplant following reduced intensity conditioning and represents a significant unmet medical need.
• Gavin MacBeath, Ph.D., Chief Executive Officer, said that they are very excited by the data and intend to launch a pivotal trial in the second half of 2025.
• Gavin MacBeath, Ph.D., Chief Executive Officer, stated that following recent feedback from the FDA, they believe they have a clear development path.

Industry Context

This announcement is significant in the context of the broader industry trend towards developing more effective and targeted therapies for cancer, particularly in the area of cell-based immunotherapies. The positive results from the ALLOHA trial and the planned pivotal trial for TSC-101 position TScan as a potential leader in the field of TCR-T therapies for hematologic malignancies.

Comparison to Industry Standards

• The reported hazard ratio of 0.30 for event-free survival in the ALLOHA trial is highly competitive compared to other cell therapies in similar indications.
• The relapse rate of 8% in the treatment arm is significantly lower than the 33% in the control arm, suggesting a strong treatment effect.
• The use of an external control arm using data from CIBMTR is a common practice in rare disease trials, which is a reasonable approach for this study.
• The company's approach to multiplex TCR-T therapy for solid tumors is aligned with the industry's focus on addressing tumor heterogeneity.
• Companies like Adaptimmune and Immatics are also developing TCR-T therapies, but TScan's approach of targeting HA-1 and HA-2 antigens in hematologic malignancies and its ImmunoBank for solid tumors differentiates it from its competitors.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical data and clear regulatory path.
• Patients with hematologic malignancies may benefit from the potential approval of TSC-101.
• Employees may be motivated by the progress of the company's clinical programs.
• The company's suppliers and partners may see increased business opportunities.

Next Steps

• Continue to enroll ALLOHA Phase 1 study using commercial manufacturing process at TScan.
• Transfer commercial process to a third-party contract development and manufacturing organization (CDMO).
• Work to reach final agreement with FDA on its pivotal trial design.
• Initiate registrational trial with clinical supply manufactured at CDMO.
• Launch pivotal study in the second half of 2025.
• Open expansion cohorts at proposed RP2D in 2025.
• Dose first multiplex patient in Q1 2025.
• Obtain safety and response data for multiplex therapy in H1 2025.

Key Dates

Keywords

TCR-T therapy, hematopoietic cell transplantation, relapse, acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, event-free survival, solid tumors, ImmunoBank, multiplex TCR-T, TSC-100, TSC-101, FDA, clinical trial